ClinicalTrials.Veeva

Menu

GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses

UNC Lineberger Comprehensive Cancer Center logo

UNC Lineberger Comprehensive Cancer Center

Status

Completed

Conditions

Kidney Tumor
Small Renal Mass

Treatments

Procedure: Small Renal Mass Biopsy
Other: No Small Renal Mass Biopsy

Study type

Interventional

Funder types

Other

Identifiers

NCT03819569
LCCC 1834

Details and patient eligibility

About

Purpose: The purpose of this study is to evaluate the role of renal mass biopsy on decision-making for patients presenting with clinical T1 kidney tumors. This study also incorporates integrated biomarker study to compare the genomic data obtained through biopsy tissue to genomic information from surgical data.

Full description

Primary Objective

  1. To compare the decisional conflict between patients who undergo renal mass biopsy during their evaluation for SRMs versus those who do not.
  2. To validate the concordance of RNA sequencing (RNAseq) and genomic-based risk stratification molecular biomarkers between renal biopsy tissue and surgical (nephrectomy) specimen tissue.

Secondary objective

  1. To characterize the impact of biopsy on patient reported anxiety and uncertainty, assessment of cancer care communication, and satisfaction with cancer care.

Enrollment

265 patients

Sex

All

Ages

18 to 95 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Ages 18 - 95
  • Have a small renal mass ≤7 cm on cross-sectional radiologic study evaluated at the University of North Carolina (UNC) Urology or the UNC Cancer Hospital.
  • Has voluntarily provided signed informed consent to participate and HIPAA authorization for the release of personal health information
  • Willing and able to complete patient-reported outcome questionnaires
  • Willing to have extra cores taken for research during the standard-of-care biopsy procedure
  • Willing to allow surgical specimens to be used for research
  • Willing to undergo a blood draw to evaluate for circulating tumor DNA

Exclusion Criteria

  • Has staging information indicating locally advanced or metastatic disease.
  • Presence of transplant kidney
  • Unwilling or unable to complete informed consent
  • Previous biopsy of small renal mass.

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

265 participants in 2 patient groups

Biopsy
Active Comparator group
Description:
Subjects receive a renal cell biopsy prior to making a decision about treatment
Treatment:
Procedure: Small Renal Mass Biopsy
No Biopsy
Sham Comparator group
Description:
Subjects do not receive a renal cell biopsy prior to making a decision about treatment
Treatment:
Other: No Small Renal Mass Biopsy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems